 antitumor activ liposome-encapsul doxorubicin advanc breast cancer phase II studi previou studi anim liposome-encapsul doxorubicin led cardiac toxic free doxorubicin antitumor activ phase studi led maximum dose dose-limit toxic granulocytopenia led patient advanc measur breast cancer led dose week intraven infus regress diseas patient patient complet regress index lesion mean durat respons month hematolog toxic grade leukopenia patient gastrointestin toxic mucos mild toler alopecia patient complet twelv patient cumul dose led radionuclid ventriculogram patient cumul dose endomyocardi biopsi biopsi result billingham cumul led dose chang mild myofibrillar loss dilat sarcoplasm reticulum cardiac myocyt patient decreas left ventricular eject fraction patient total dose led declin left ventricular eject fraction clinic evid congest heart failur billingham grade endomyocardi biopsi